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Abstract
The plasma prekallikrein gene is expressed in many dif-
ferent human tissues at distinctly different levels and
therefore tissue-specific control of the gene transcription
is likely. In this study we demonstrate that transcription
of the plasma prekallikrein gene can be initiated at mul-
tiple sites, for which at least four different promoters are
utilized. A comparison of the genomic and mRNA
sequences of mouse plasma prekallikrein revealed that
the sequence segment that was formerly regarded as the
first exon of the mouse plasma prekallikrein gene con-
sists of three exons, with the first exon localized 14.2 kbp
upstream of the translation start. For the rat and human
plasma prekallikrein genes, in silico analysis suggested
an analogous exon-intron organization. Determination of
the transcription start sites showed that in both mouse
and human, the proximal and distal regions could be util-
ized for transcription initiation; however, the proximal
region is preferred. A deletion mutation analysis of the
proximal promoter region using a 1.7-kbp segment
revealed a strong activating region immediately upstream
of the known mRNA, followed by both a modest repres-
sor and an enhancer region.
Keywords: alternative promoter; alternative
transcription start site; Inr element; plasma kallikrein;
plasma prekallikrein; promoter activity; TATA box;
transcription start site; 59-untranslated region
heterogeneity.
Introduction
Plasma prekallikrein (PPK), the zymogen of the serine
protease plasma kallikrein, is synthesized as a single-
chain glycoprotein in hepatocytes and secreted into
the bloodstream (Bhoola et al., 1992) where it circu-
lates mainly as a complex with high-molecular-weight
kininogen (HMWK). In vitro, conversion of plasma pre-
kallikrein to active plasma kallikrein is achieved by cleav-
age of the peptide bond Arg371-Ile372 either in a fluid
phase by a factor XII fragment or on negatively charged
surfaces by activated factor XII (factor XIIa) with HMWK
as the cofactor (contact activation). Factor XIIa-inde-
pendent PPK activation has been shown to occur on the
surface of endothelial cells by a protease (Colman and
Schmaier, 1997; Motta et al., 1998, 2001) which has been
identified by Shariat-Madar et al. (2002) as prolylcar-
boxypeptidase. In addition, it has been observed that
activation of prekallikrein complexed to HMWK on endo-
thelial cell surfaces may also be catalyzed by heat shock
protein 90 (Joseph et al., 2002).
Biological activities attributed to PPK circulating in
the blood are: involvement in the activation of neutrophils
(Schapira et al., 1982, 1983; Wachtfogel et al., 1983);
activation of the C3 convertase of the alternative path-
way (DiScipio, 1982); induction of the fibrinolytic cascade
by converting the pro-urokinase plasminogen activator
to an active molecule (Ichinose et al., 1986; Hauert et al.,
1989); and the release from HMWK of bradykinin, which
regulates cellular events through specific receptor-cou-
pling of second messengers (Blais et al., 2000; Blaukat,
2003). The formerly accepted role of PPK, together with
factor XII and HMWK, in the coagulation pathway is no
longer sustainable, since deficiencies of these proteins
in plasma do not result in bleeding disorders (Colman
and Schmaier, 1997; Davie, 2003).
Recently we demonstrated that the PPK gene is tran-
scribed not only in the liver, but also at distinctly different
levels in non-hepatic human tissues (Neth et al., 2001).
Furthermore, in immunocytochemical studies plasma
kallikrein/PPK has been specifically visualized in several
human tissues, such as pancreas, kidney, testis and
stomach (unpublished data). Since PPK in the blood orig-
inates essentially or totally from the liver (Colman and
Wong, 1979), we concluded that the extrahepatically
synthesized PPK has special functions at or near the site
of its synthesis.
Interestingly, novel biological roles of plasma kallikrein
that fit into the concept of local PPK functions have been
reported recently. Hecquet et al. (2002) demonstrated
that plasma kallikrein, as well as some other proteases,
activates bradykinin B2 receptor directly, independent of
kinin release. Selvarajan et al. (2001) recently reported
that plasma kallikrein is required for adipogenesis. The
enzyme mediates activation of a plasminogen cascade,
which promotes adipocyte differentiation by degrading
the fibronectin-rich extracellular matrix of preadipocytes.
Peek et al. (2002) found that plasma kallikrein, as well
as coagulation factor XI, can activate pro-hepatocyte
growth factor. Hepatocyte growth factor (HGF) is the
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Table 1 Alignment of mouse mRNA to mouse, rat and human genomic sequences.
Exon and intron numbering E1a I1a E1b I1b E1c
Length of newly identified mouse exons and introns 87 1271 226 11852 291
Segments of mouse exons that map to rat genomic sequence 3–87 1–226 2–290
Length of mapping rat segments 85 228 290
Identity, % 94 92 85
Gap, % 0 1 1
Length of rat intervening sequences 1271 16400
Segments of mouse exons that map to human genomic sequence 6–85 1–175 80–258
Length of mapping human segments 80 175 188
Identity, % 81 85 74
Gap, % 2 0 9
Length of human intervening sequences 1198 16734
Mouse exons mE1a, mE1b and mE1c were identified by mapping mouse PPK mRNA to the mouse genomic sequence.
The analogous rat and human exons E1a, E1b and E1c result from BLAST alignment of mouse PPK mRNA to rat and
human genomic sequences (see the materials and methods section).
Figure 1 Organization of the 59-regions of mouse, rat and
human PPK genes.
The mouse exon-intron structure was obtained by mapping
mouse PPK mRNA to the mouse genomic sequence. The puta-
tive exons E1a, E1b, and E1c (open boxes) for rat and human
were assigned by aligning mouse mRNA to rat and human
genomic sequences. The known human and rat exons 1 and 2
are shown as filled boxes; the start codons located at position
2 of exons mE2, rE2 and hE2 are indicated.
ligand for the tyrosine kinase receptor c-Met, and thus
plasma kallikrein may also regulate processes that in-
volve the HGF/c-Met signaling pathway. Akita et al.
(2002) investigated the molecular mechanism underlying
impaired liver regeneration by circulating endotoxin after
partial hepatectomy and provided convincing evidence
that this impairment is caused by plasma kallikrein-medi-
ated activation of latent transforming growth factor b
(TGF-b). Interestingly, we recently found co-localization
of PPK and TGF-b1 in the tubules and mesangial cells
of normal renal parenchyma and the tissue adjacent to
clear cell carcinoma of the human kidney (unpublished
data).
Synthesis in multiple tissues and involvement in vari-
ous physiological processes suggest that a distinct reg-
ulation of PPK synthesis in particular tissues and cells is
required, and we set out to characterize the transcrip-
tional control of human PPK gene expression. In the cur-
rent study, we show that the transcription of human PPK
gene can be initiated at multi-
ple sites, which are up to 23 kbp apart, indicating that
different promoters can be utilized, presumably in a tis-
sue- and/or cell type-specific manner. Alternatively
spliced mRNA variants were detected, some of them
indicating the existence of N-terminally truncated PPK
molecules. The major transcription start sites are close
to the 59-end of the known PPK mRNA (Chung et al.,
1986). Examination by deletion analysis of the 1.7-kbp
region upstream of the PPK mRNA for promoter activity
showed that it contains both transcription-enhancing and
-repressing segments.
Results
Comparison of the mRNA and genomic sequences
of human, mouse and rat PPK
A comparison of the known PPK mRNAs from mouse
(Seidah et al., 1990; NM_008455), rat (Seidah et al.,
1989; Beaubien et al., 1991; NM_012725) and human
(Chung et al., 1986; NM_000892) showed that the three
59-UTRs vary significantly in length, encompassing 605,
167 and 71 bp, respectively. Therefore, the question
arose as to whether the known human mRNA represents
a full-length transcript of the PPK gene, and hence we
examined this aspect by in silico analysis.
Mapping of the mRNAs to their respective genomic
sequences confirmed for human (Yu et al., 2000) and rat
(Beaubien et al., 1991) that the PPK genes consist of 15
exons with the coding sequence starting at position 2
of exon 2. In contrast, for mouse our alignment revealed
that what was previously regarded as mouse exon 1
consists of three exons of 87, 226 and 291 bp (tentatively
designated mE1a, mE1b and mE1c), which are separated
by introns I1a and I1b of 1271 and 11 852 bp, respec-
tively (Table 1, Figure 1).
The finding that mouse PPK mRNA contains two addi-
tional exons led to the view that analogous transcripts
may also be formed in human and rat. In order to exam-
ine this possibility, we aligned the mouse exons mE1a,
mE1b and mE1c to human chromosome 4 and rat chro-
mosome 16, where the PPK genes are localized. As
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Table 2 Transcription start sites in human liver, pancreas,
kidney and HepG2 cells.
Position of
TSS
Liver Pancreas Kidney HepG2
UTR -127 1
UTR -36 1
UTR -11 4
UTR -5 1
E1 q1 5 3 2 1
E1 q3 1
E1 q4 1
E1 q6 3 3 1
I1 136 1
I1 243 1
I1 248 1
I1 265 1
I1 334 1
I1 436 1
E2 q75 1
E2 q76 2
E2 q77 1
TSS, transcription start site; UTR, 59 untranslated region; E1,
E2, conventional exons 1 and 2; I1, intron 1. The numbering
of positions in the 59-upstream region and in exons 1 and 2 is
relative to the 59-end of the known mRNA sequence; in intron
1 the numbering refers to the 59-end of intron 1. Numbers in
columns 3–6 indicate the number of clones with the respective
transcription start site.
shown in Table 1 and Figure 1, nearly the complete exons
mE1a, mE1b and mE1c mapped to the rat genomic
sequence with identities between 85% and 94%. In anal-
ogy to the new mouse exons, these segments were pro-
visionally designated rE1a, rE1b and rE1c. The
intervening sequences rI1a and rI1b were 1271 and
16 400 bp in length, respectively.
By alignment of the three mouse exons to the human
genomic sequence, three segments of high similarity
were also found (designated hE1a, hE1b, hE1c; Table 1,
Figure 1), whereby hE1c did not overlap the complete
conventional human exon 1, but only 48 bp of its 59-end.
The lengths of the intervening sequences correspond-
ing to mouse introns 1a and 1b (1271 and 11 852 bp)
were 1198 and 16 734 bp, respectively.
Taken together, comparison of the mRNA sequences
of human, mouse and rat, and the alignment of the newly
identified first three mouse exons to the rat and human
genomic sequences suggested that the known rat and
human mRNA sequences do not represent full-length
transcripts of the PPK gene. Transcripts of the PPK gene
with 59-extensions (as compared to the known mRNAs)
containing two additional exons might also exist in these
two species. Conversely, it seemed possible that tran-
scription of the mouse PPK gene can also be initiated
within exon mE1c at start sites analogous to those of rat
or human.
The known human PPK mRNA is a full-length
transcript and the transcriptional start sites in
human liver, pancreas and kidney are diverse
With the aim of characterizing the promoter of the human
plasma prekallikrein gene, we determined first whether
the known mRNA sequence (Chung et al., 1986) repre-
sented a full-length transcript and whether the same
transcription starts were utilized in different tissues. To
answer this question, transcription initiation sites were
determined by RNA ligase-mediated rapid amplification
of 59-cDNA ends (RLM-RACE) with the PPK-specific
primers positioned in exon 2 using poly(A)q mRNA from
human liver, pancreas and kidney, the three tissues with
the highest PPK mRNA expression. The relative expres-
sion levels in liver, pancreas and kidney are 100%, 68%
and 25%, respectively (Neth et al., 2001).
By analysis of 31 clones from the three tissues, 15 dif-
ferent sites for transcription initiation were detected
(Table 2); the distance on the genomic sequence be-
tween the most upstream and most downstream tran-
scription start sites was 811 bp. Transcription start sites
at or near positionq1 of the known mRNA were detected
in liver, pancreas and kidney, proving that the known
human PPK mRNA represents a full-length transcript.
Additional transcription start sites, further upstream or
downstream of positionq1, were found exclusively in the
kidney (Table 2): two transcripts had 59-extensions of 36
and 127 bp, and six had initiation sites within intron 1.
Accordingly, the segment of intron 1 upstream of the
respective transcription start sites, as well as the con-
ventional exon 1, are included in the promoter region. In
this type of transcript the conventional first exon is miss-
ing, even though the complete PPK protein is encoded.
Most interestingly, three additional transcription start
sites detected in the kidney were located in exon 2 in
positionsq75,q76 andq77 (the numbering refers to the
known mRNA sequence); hence, the promoter region
includes the complete intron 1 (607 bp, NT_022792; or
608 bp, AF232734 and our own sequencing results) and
the conventional exon 1 (70 bp). Furthermore, since the
start sites are downstream of the start codon at q72,
translation has to start at an ATG codon further down-
stream, causing a truncation by at least 38 amino acids.
As a result, a PPK molecule would be produced that
would be lacking not only the signal peptide, but also at
least 19 amino acids of the mature protein.
The human PPK gene has transcription initiation
sites analogous to mouse and vice versa
To address the question as to whether transcription start
sites analogous to mouse PPK can be used in human
and vice versa, we carried out a series of 59-RLM-RACE
analyses with mRNA from human and mouse liver. Using
human liver mRNA and the gene-specific primer located
in hE1a (cf. Figure 2), we detected two types of tran-
scripts (types I and II, cf. Figure 2) with the transcription
start sites 18.5 and 22.5 kbp upstream of the previously
reported human PPK mRNA (Yu et al., 2000). Type I tran-
scripts (ns2) started at positions resulting in lengths of
hE1a of 83 and 110 bp (the 39-end of hE1a identified by
the alignment with mouse exon 1, cf. Table 1, was cor-
rected following the GT-AG rule). The type II transcript
(ns1) contained two additional exons upstream of hE1a.
The first upstream exon, hE1a-1 (135 bp), was separated
from hE1a by 93 bp, and the second upstream exon,
hE1a-2 (285 bp), from hE1a-1 by a 3562-bp intron.
Using mouse liver mRNA and the gene-specific primer
positioned in mE1c, we identified five different transcrip-
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Figure 2 Determination of transcription initiation sites of the mouse and human PPK genes by RLM-RACE.
The positions of gene-specific primers (arrowheads) were located in mouse exons mE1c and mE1a, and in human exons hE2 (not
shown) and hE1a. Numbers indicate the lengths of exons and introns in bp. Filled boxes represent the exons detected by RLM-
RACE and open boxes the exons identified by alignment of mouse mRNA to the genomic sequences. Roman numerals indicate the
different types of transcripts (cf. results section).
tional start sites within mE1c (Figure 2). The resulting
mE1c lengths of 69, 77, 80, 84 and 96 bp are similar in
size to the conventional human exon 1. No transcripts
corresponding to the known mouse mRNA (i.e., starting
with mE1a) were detectable in this experiment. Therefore,
we carried out a second 59-RACE with the gene-specific
primer in mE1a (Figure 2). We found two types of tran-
scripts: type I (ns2) started with mE1a, whereby the
lengths of mE1a were 62 and 147 bp. Transcripts of type
II (ns2) had an additional upstream exon, mE1a-1, which
was separated from mE1a (180 bp) by an intron of 97bp.
For mE1a-1, two transcription start sites were obtained,
causing mE1a-1 lengths of 66 and 89 bp. No transcrip-
tion start site representing exactly the 59-end of the
published mouse PPK mRNA (Seidah et al., 1990) was
detected.
Additional evidence for the use of multiple transcription
initiation sites was gained from a search of EST data-
bases. For human, two sequences were found corre-
sponding to our type II transcript (two additional exons
upstream of hE1a; Figure 2), and two sequences starting
at positionsq3 andq9 of the known mRNA. For mouse,
three sequences were detected with the 59-ends in mE1a,
whereby none of the sequence start sites coincided
exactly with that of the known mouse PPK mRNA. Fur-
thermore, six sequences were found with one (our type
II, cf. above) to three additional upstream exons. A total
of 13 EST sequences had start sites within mE1c; the
resulting exon lengths would be 26, 28, 35, 50, 54, 55,
70, 71, 76, 98 and 119 bp, and thus would be similar to
the size of the conventional human exon 1. A search of
the Database of Transcriptional Start Sites (Suzuki et al.,
2002) produced no results for human, whereas for mouse
10 transcription start sites within mE1c are available,
resulting in lengths of mE1c of 26, 50, 54, 55, 70, 76 and
96 bp, but no distal transcription start sites are given.
Taken together, the RLM-RACE and the data mining
results demonstrate that both in mouse and human, tran-
scription of the PPK gene can be initiated at sites in
regions that are distantly apart. Form the experimental
results it can be concluded that transcription of the
human PPK gene in the liver can be driven by three dif-
ferent promoters, namely the proximal promoter preced-
ing position 1 of the conventional human exon 1, hE1,
and two distal promoters located upstream of hE1a and
hE1a-2, approximately 18.5 and 22.5 kbp upstream of
hE1 (Figure 2).
Transcriptional start sites in HepG2 cells
The human hepatoma cell line HepG2, which is widely
used as a model system for hepatocytes, expresses PPK
mRNA, as we had previously ascertained by RT-PCR
(data not shown). Since we intended to use this cell line
for promoter activity studies, we examined which tran-
scription start sites are utilized in HepG2 cells. DNA
sequence analysis of six PCR products obtained by
RLM-RACE revealed that transcription of the PPK gene
in HepG2 cells starts in the same region as in liver and
pancreas (Table 2). The initiation sites identified repre-
sented positions -11, -5 andq1. The similarity or identity
of the start sites to those found in liver and pancreas
indicates that in HepG2 cells the same promoter region
is effective, which justified employing HepG2 cells as a
model for studying the activity of the proximal PPK
promoter.
Deletion-mutation analysis of the proximal PPK
promoter region
A segment comprising 1675 bp of the 59-flanking region
and 22 bp of the conventional exon 1 of human PPK
gene was cloned by employing the ‘Genome Walker’
technique. The segment was linked to the 59-end of the
promoterless secretory alkaline phosphatase reporter
gene of the pSEAP2-Basic plasmid. This construct was
transiently transfected into HepG2 cells and the promo-
ter activity of the construct was determined by measuring
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Figure 3 Deletion mutation analysis of the human PPK pro-
moter region.
The 59- and 39-ends of each deletion mutant are given on the
left-hand side. Each construct was cloned into the pSEAP2
reporter gene plasmid and transiently transfected into HepG2
cells (in triplicate) and the supernatant was analyzed for alkaline
phosphatase activity. Controls, indicated as Basic and HepG2,
were HepG2 cells transfected with the reporter gene plasmid
without insert and non-transfected HepG2 cells. The activity is
given in relative luminescence units; the bars indicate the
mean"SD (ns3) of the SEAP activity.
the alkaline phosphatase activity released into the super-
natant. The promoter activity of the -1675/q22 construct
was approximately 43-fold higher than of pSEAP2-Basic
(Figure 3), indicating that the sequence encompasses a
promoter region. Subsequent in silico analysis using
MatInspector (Quandt et al., 1995) revealed that numer-
ous consensus sequences for activating and repressing
transcription factors are present within the -1675/q22
segment. Taking into consideration the location of poten-
tial transcription factor binding sites, nine deletion vari-
ants of the full-length -1675/q22 construct were pre-
pared and examined for transcriptional activity. Figure 3
shows that the 10 reporter gene constructs displayed
significantly different promoter activity. The highest activ-
ity was observed for the full-length construct -1675/q22
(arbitrarily set to 100%). Deletion of the sequence -1675
and -1488 resulted in decrease in activity to approxi-
mately 45%. Subsequent deletion of -1488 to -1298,
-1298 to -1176, and -1176 to -688 led to a gradual activ-
ity recovery to approximately 67%. Further deletion of
sequences -668 to -452 and -452 to -205 caused a
decrease to 36%; this activity remained unchanged by
deletion to -152. Removal of the next 50 bp generated a
sharp drop to 9% and deletion of the sequence -102/
-23 completely abolished this residual promoter activity.
Discussion
Experimental results and data mining for transcription
start sites indicated that transcription of the PPK gene in
human and mouse liver could be initiated in three differ-
ent regions (Figure 2). However, neither in mouse nor in
human were the distal initiation sites detected when 59-
RLM-RACE experiments were carried out with the gene-
specific primers located downstream of the proximal
initiation sites, even though the distal start sites must in
principle be detectable by such an experiment. However,
the distal transcription start sites were detectable when
the gene-specific primers in 59-RLM-RACE experiments
were located in the distal exons mE1a and hE1a, respec-
tively (Figure 2), namely, when experimental conditions
selective for detecting the distal transcription start sites
were chosen. This finding indicates that the proximal
start sites represent the major region for transcription
initiation. If transcription is mainly initiated near the prox-
imal start site and the gene-specific primer located
downstream to this site, then the number of formed short
transcripts will be larger than the number of the long
ones, which start at the distal transcription start sites.
Thus, it would have been necessary in our experiments
to screen a much larger number of clones than the 16
we examined to identify the long transcripts in addition
to the short ones. Interestingly, the known mouse PPK
mRNA described by Seidah et al. (1990) represents one
of the long transcripts. Obviously, the authors were quite
fortunate in finding one of these rare long transcripts by
chance and against statistical expectancy. Taken to-
gether, our experiments elucidated that in both mouse
and human liver transcription of the PPK gene can be
initiated in at least three different regions, but the major
transcription start region is the proximal one.
A comparison of the proximal transcription start sites
in the human liver, pancreas and kidney, the three tissues
with the highest PPK mRNA expression levels (Neth
et al., 2001), unveiled tissue-dependent utilization of tran-
scription starts (Table 2) and promoters. In the liver and
pancreas, all start sites coincided with or were close
to positionq1 of the known PPK mRNA, whereas in the
kidney additional start sites upstream and downstream
ofq1 were detected. For all the start sites downstream
of positionq1 the promoter differs substantially from the
one upstream of q1, as it includes part of intron 1 and
exon 1 and can be regarded as alternative promoter(s).
In all resulting transcripts the first exon will be missing.
Moreover, those transcripts starting downstream of the
start codon would give rise to a PPK molecule lacking
both the signal peptide and at least 19 amino acids of
the mature protein. Accordingly, because of the missing
signal peptide, this molecule cannot be directed to the
secretory pathway and therefore an intracellular role of
the truncated PPK could be assumed. However, so far
we have failed to demonstrate the existence of such a
truncated PPK protein by Western blot experiments with
human tissue extracts (data not shown).
Diverse transcription initiation is widespread through-
out the genome, as revealed by Suzuki et al. (2001) who
determined 5880 transcription start sites in 276 human
genes in a 59-full-length enriched cDNA library. In approx-
imately 75% of these genes the most upstream and
downstream transcription start sites were separated by
up to 100 bp, and in ;25% the transcription starts were
between 100 and)200 bp apart. Of the 276 genes, 15%
had tightly clustered start sites and in only five genes did
the transcription start site map to a single position. At
present no analysis is available on whether different or
single promoters drive gene transcription from multiple
transcription start sites. However, it seems likely that a
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Figure 4 Transcription start sites of the PPK gene determined in human liver and pancreas.
A putative TATA box is shown in bold font. Experimentally determined transcription start sites are indicated by bold italics; the numbers
are relative to the start site of the known mRNA. Consensus sequences of Inr elements are indicated below the sequence.
single promoter has the ability to drive transcription from
different transcription start sites when they are located
within an approximately 50-bp-wide region (Suzuki et al.,
2001). Such use of a single promoter is certainly the case
for the tightly clustered proximal transcription starts of
the PPK gene.
The use of alternate promoters and multiple transcrip-
tion start sites for a single gene has been described for
multiple mammalian genes, and is regarded as part of
the elaborate mechanisms that have evolved in multicel-
lular organisms to provide a means of highly diversified
temporal and spatial control of gene expression (Lemon
and Tjian, 2000; Hochheimer and Tjian, 2003). In the case
of PPK, the utilization of alternative promoters and/or
alternative transcription start sites results in the expres-
sion of at least 20 different transcripts (Table 2 and Figure
2). This diversity of transcripts infers an intricate temporal
and cell type-specific control of expression of the PPK
gene and provides circumstantial evidence supporting
our concept that PPK/plasma kallikrein plays hitherto
unknown diverse functional roles in various tissues and
cell types (Hermann et al., 1999; Neth et al., 2001). Sup-
porting evidence for cell type-specific expression is also
gained from our ongoing immunocytochemical studies
(unpublished data), which for example show intense
staining of PPK in distinct cells of human kidney tubules.
The experimental and data mining results demonstrate
that, at least in the liver, it is the proximal region that is
mainly used for transcription initiation. Therefore, for our
studies on the regulation of expression of the human PPK
gene, we chose to concentrate first on this major tran-
scription start region. A TATA-box motive was identified
at -41 to -32 (relative to the start of the known mRNA;
Figure 4) which is a few bp upstream of the region most
preferred for a TATA-box (Bucher, 1990), but can be
expected to be a functional core promoter element. Con-
sensus sequences of a second core promoter, the initi-
ator element (Inr) (Smale, 1997), were identified for five
of the six transcription start sites in liver, pancreas and
HepG2 cells (Figure 4). No downstream promoter ele-
ment (DPE) motive (G-A/T-C-G in theq30 region) (Burke
and Kadonaga, 1997; Kutach and Kadonaga, 2000) was
detectable. Taken together, the core promoter region of
the PPK gene contains both a TATA-box and Inr motives
in positions that can direct transcription initiation to any
of the proximal transcription start sites found in liver, pan-
creas and HepG2 cells, whereby the action of the
motives may be paired or independent.
In our promoter activity study the high transcriptional
activity of the -1675/q22 reporter gene construct dem-
onstrated that the 1.7-kbp sequence upstream of hE1
contains cis-acting elements important for the regulation
of PPK gene transcription. Deletion mutation analyses
(Figure 3) identified two regions with high stimulatory
effects on transcription. The first one, the putative pro-
moter, was found within the proximal sequence from
-668 bp to the transcription start site, with the cis-acting
elements mainly localized in the segments -102/-152 and
-205/-452. The second one was detected in the 189-bp
region -1488 to -1675 and is presumably an enhancer
region. Transcription-repressing activity was found in
the region -668 to -1488 between the promoter and the
enhancer, mainly localized within the segments -668 to
-1176 and -1298 to -1488. In silico searches for tran-
scription factor binding sites in the promoter region were
carried out using two different methods (Quandt et al.,
1995; Lenhard et al., 2003). However, even with the most
stringent parameters, too many potential transcription
factor binding sites were found to allow for a conclusive
decision on which sites are biologically functional and
which are ‘innocent bystanders’. Therefore, further
experiments have been designed to identify the critical
binding sites.
PPK mRNA is expressed in many human tissues at
different levels (Neth et al., 2001) and PPK participates
as a protease in various biological processes. Therefore,
in order to comply with the spatially and temporally var-
ying demands for the functional activity of PPK, distinct
mechanisms for fine-tuned transcriptional regulation of
the PPK gene may be expected. In accordance, our
experimental and data mining investigations show that at
least four promoter regions and diverse transcription start
sites can be utilized, and tissue-dependent alternative
use of promoters and transcription starts is evident from
a comparison of the start sites in liver and kidney.
Materials and methods
Determination of transcriptional start sites of PPK
Transcriptional start sites were determined by performing RNA
ligase-mediated rapid amplification of 59-cDNA ends (RLM-
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Table 3 Gene-specific primers for RLM-RACE.
Designation Position Sequence (59–39)
Human
hP-r139 Exon 2 19560916–19560895 TAGCAAACAAGGAAATGAAATA
hP-r124-Nhe Exon 2 19560901–19560876 GCTAGC-TGAAATAAGTTGCTTGCTTGAATAAA
hE1a-or71 hE1a 19541931–19541910 GCCAGCAGAGAAGGGCACGTAG
hE1a-ir47 hE1a 19541907–1941884 ATATGGATGGCGCCCTTGTGCATT
Mouse
mP-or9146 mE1a 75–49 GAGGTCCAGCAGAAAATGGCACATAGG
mP-ir9126 mE1a 55–29 ACATAGGCATAGGGATGGCGTCCTTGG
mP-or22799 mE1c 605–583 CCTGGAAGGATGGTCACGTTGTG
mP-ir22771 mE1c 577–550 GGAGGAGAGGGAGTCTTCACATGAAGAT
The position numbers refer to human NT_022792.15 and mouse PPK mRNA NM_008455.1. Underlined
nucleotides indicate an NheI recognition sequence.
Table 4 Primers used for the construction of reporter plasmids.
Promoter Position Nucleotide sequence (59–39)
mutant
-23/q22 -23/-2 ACGCGT-AATATTGCCTGCAGTGCCACAT
-102/q22 -102/-81 ACGCGT-GATGTTCATGGAATATGTTGAC
-152/q22 -152/-131 ACGCGT-GACATCACTCCCTGAAATAGTT
-205/q22 -205/-184 ACGCGT-GGGATGAGCGCTAGAAACTCCT
-452/q22 -452/-431 ACGCGT-GTGGTGAAGTTAGGTTCTATCT
-668/q22 -668/-647 ACGCGT-GCTAACGTGGAGGCTAGATAGA
-1176/q22 -1176/-1155 ACGCGT-AGTGTGGCCTTGCACTGAAGTA
-1298/q22 -1298/-1277 ACGCGT-TCTTAAGGCAATTATTTTTAGC
-1488/q22 -1488/-1467 ACGCGT-CTAGTCTGCTGCTGAAGCTGTT
-1675/q22 q22/q1 GCTAGC-TGAACGGTCTTCAAGCTGTTCT
The numbers indicate the position relative to the 59-end of the known
mRNA. Underlined nucleotides represent MluI and NheI recognition
sequences.
RACE; Invitrogen, Karlsruhe, Germany) with 250 ng of poly(A)q
mRNA from human liver, pancreas, and kidney and from mouse
liver (Clontech, Heidelberg, Germany). 59-RLM-RACE ensures
that only full-length 59-ends of mRNA molecules with an intact
Cap structure are selectively reverse transcribed and amplified
by nested PCR. For reverse transcription, random hexamer
priming was employed. The gene-specific primers used for pri-
mary and nested PCR are listed in Table 3. The PCR products
were cloned into the plasmids pCRII-TOPO or pCR4-TOPO (Invi-
trogen) and the DNA sequences of the inserts were determined
by a commercial service (MediGenomix, Martinsried, Germany).
Isolation of the prekallikrein promoter region
The upstream region of the human prekallikrein gene was cloned
using the Genome Walker Kit (Clontech). Primary and nested
PCRs were carried out with the Advantage Genomic Polymerase
Mix (Clontech) using forward primers complementary to the
adapter sequences and the gene-specific reverse primers 59-
AAT TGC TTC TTG GAG GTG AGT-39 and 59-GCT AGC TGA
ACG GTC TTC AAG CTG TTC T-39 (NheI recognition site under-
lined) which correspond to nucleotides 60–40 and 22–1 of the
prekallikrein cDNA sequence. A 1.7-kbp product was obtained,
which was cloned into the pCRII-TOPO vector and sequenced
on both strands. The plasmid was cut with MluI and NheI and
the resulting fragment was purified by agarose gel electropho-
resis and cloned into the plasmid pSEAP2-Basic (Clontech),
which was designated PPK/pSEAP2-Basic. Plasmid DNA was
isolated from 100-ml overnight cultures of single clones by the
Mobius 1000 Kit (Novagen, Bad Soden, Germany) and stored at
-208C.
Reporter plasmids
Prekallikrein promoter segments of various lengths were gen-
erated by PCR with the PPK/pSEAP2 plasmid as a template.
PCR was performed with Thermozyme (Invitrogen) using the
primers shown in Table 4. The PCR products were cloned into
the plasmid pCRII-TOPO and sequenced on both strands. Clon-
ing into pSEAP-Basic and subsequent plasmid preparation was
achieved as described above.
Cell culture, transfection, and SEAP assay
HepG2 cells were purchased from DSMZ (Braunschweig, Ger-
many) and maintained at 378C in RPMI medium (PAA, Pasching,
Austria) supplemented with 10% fetal calf serum (FCS) (PAN
Biotech, Aidenbach, Germany). Cells grown to confluence in 75-
cm2 flasks were harvested by trypsination (PAN Biotech) and
replated in 12-well plates at approximately 40% confluence (2ml
of medium per well). The cells were grown overnight at 378C in
5% CO2 to 50–70% confluence. The medium was replaced by
0.9 ml of fresh RPMI medium with 10% FCS, and 0.1 ml of
transfection mixture containing 3 ml of FuGENE 6 transfection
reagent (Roche, Mannheim, Germany) and 1 mg of DNA in RPMI
medium was added.
Secretory alkaline phosphatase (SEAP) activity was deter-
mined using the chemiluminescent SEAP assay system (Clon-
tech). After 24 and/or 48 h, 15-ml aliquots from each cell culture
supernatant were transferred into the wells of a 96-well micro-
test plate; 45 ml of dilution buffer was added and the plate was
incubated for 30 min at 658C to inactivate endogenous alkaline
phosphatase. After cooling, 60 ml of assay buffer and, after
5 min at room temperature, 60 ml of CSPD substrate solution
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(Clontech) were added. The luminescence was quantified after
10 min.
BLAST analyses and search for a TATA box
For the alignment of sequences, the NCBI program BLAST 2
Sequences (Tatusova and Madden, 1999) was employed. The
settings were: match, 1; mismatch, -2; gap open, 1; gap exten-
sion, 1; x_dropoff, 50; expect, 10; wordsize, 10; and filter, yes.
Accession numbers of the PPK mRNA sequences are: human,
NM_000892.2; mouse, NM_008455.1; and rat, NM_012725.1.
Accession numbers of the genomic sequences are: human,
NT_022792.15; mouse, NW_000342.1; and rat, NW_043042.1.
For the TATA-box search, the program accessible at
www.itb.cnr.it/webgene was used.
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